

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number		Divisional f 09/239,387			
Filing Date		February 28, 2002			
First Named Inventor		Bruce A. Yanker			
Group Art Unit		 			
Examiner Name		 			
Attorney Docket Number		CMCC 654 DIV (2)			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
12		WO	95/06470	A1	Merck & Co., Inc.	03-09-1995		
		WO	97/48701	A1	Pfizer, Inc.	12-24-1997		
		WO	99/38498	A1	Warner-Lambert Company	08-05-1999		
		WO	98/47518	A1	Europaisches Laboratorium for Molekular Biologie	10-29-1998		
		WO	99/15159	A1	Nova Molecular, Inc.	04-01-1999		

Examine Signature	Date Considered 6/10/05
-------------------	-------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	Divisional of 09/239,387
		Filing Date	February 28, 2002
		First Named Inventor	Bruce A. Yanker
		Group Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	CMCC 654 DIV (2)	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ALLEN, et al., "A noninstrumented quantitative test system and its application for determining cholesterol concentration in whole blood," <i>Clin Chem</i> 36(9):1591-7 AN-113:207679 CA (1990).	
		BROWN, et al., "A receptor-mediated pathway for cholesterol homeostasis," <i>Science</i> 232(4746):34-47 (1986).	
		BUSCIGLIO, et al., "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells," <i>Proc. Nat. Acad. Sci.</i> 90, 2092-2096 (1993)	
		FARRER, et al., "Assessment of Genetic Risk for Alzheimer's Disease among First-Degree relatives," <i>Ann. Neurol.</i> 25: 485-492 (1989)	
		FREARS, et al., "The role of cholesterol in the biosynthesis of beta-amyloid," <i>Neuroreport</i> 10(8):1699-705 (1999).	
		GOATE, et al., (1991) "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> 349, 704-706).	
		JARVIK, et al., "Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study," <i>Neurology</i> 45(6):1092-96 (1995).	
		MANN and ESIRI, "The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's Syndrome," <i>J. Neurol. Sci.</i> 89, 169-179 (1984).	
	MCKHAHN, et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," <i>Neurology</i> 34:939-944 (1984)		
	REIMAN, et al., "Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ϵ 4 Allele for Apolipoprotein E," <i>N.E.J.Med.</i> 334, 752-758 (1996)		

Examiner's Signature		Date Considered	6/10/03
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	Divisional f 09/239,387
		Filing Date	February 28, 2002
		First Named Inventor	Bruce A. Yanker
		Group Art Unit	
		Examiner Name	
Sheet 3 of 3	Attorney Docket Number	CMCC 654 DIV (2)	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SELKOE, D.J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <i>Science</i> 275, 630-631 (1997))	
		SPARKS, D.L., "Intraneuronal β -Amyloid Immunoreactivity in the CNS," <i>Neurobiology of Aging</i> . 17, 291-299 (1996)	
		SPARKS, et al., "Dietary cholesterol induces Alzheimer-like β -amyloid immunoreactivity," <i>Nutr., Metab. Cardiovasc Dis.</i> 7(3):255-266 AN-127:135116 CA (1997).	
		STRITTMATTER, et al., "Apolipoprotein E: High-avidity binding to β -amyloid and increases frequency of type 4 allele in late-onset familial Alzheimer disease," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:1977-1981 (1993),	
		TANIGUCHI, et al., "Method for assaying soluble amyloid precursor protein [APP]," Eur Pat Appl. AN-127-106355 CA (1997).	
		VAN DUIJN, et al., "Familial Aggregation of Alzheimer's Disease and Related Disorder's: A Collaborative Re-Analysis of Case-Control Studies," <i>Int. J. Epidemiol.</i> 20 (suppl 2), S13-S20 (1991)	
		WISNIEWSKI, et al., "Is Alzheimer's disease an apolipoprotein E amyloidosis?" <i>Lancet</i> 345(8955):956-8 (1995).	
		YANKNER, "Mechanisms of Neuronal Degeneration in Alzheimer's Disease," <i>Neuron</i> 16:921-932. (1996).	

Examiner's Signature		Date/Considered	6/14/03
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.